When the Nerves Don’t Recover: Understanding Chemotherapy-Induced Peripheral Neuropathy (CIPN)

One of the most distressing side effects of chemotherapy isn’t always the one people expect. It doesn’t show up on scans. It doesn’t get much airtime in the consult room. And yet for many patients, it lingers long after treatment has ended, quietly shaping how they move through the world.

Chemotherapy-induced peripheral neuropathy — CIPN — is not just “a bit of tingling.”
It is pain, numbness, burning, pins and needles, weakness, loss of balance, loss of confidence, and for some, a constant reminder of what the body has been through.

And perhaps most frustrating of all: patients are often told to “wait and see.”

Chemotherapy works, in part, by targeting rapidly dividing cells. But nerves are metabolically active, highly sensitive structures with limited regenerative capacity. Many common chemotherapeutic agents — particularly platinum compounds, taxanes, and vinca alkaloids — disrupt mitochondrial function, impair axonal transport, increase oxidative stress, and trigger neuroinflammation.

The result is damage to peripheral nerves that may take months or years to recover — if they recover at all.

What makes CIPN so difficult is that it sits at the intersection of multiple systems:

• mitochondrial dysfunction

• oxidative stress

• inflammatory signalling

• impaired nerve repair

• altered pain perception

There is no single lever to pull. Which is why simplistic solutions so often fail.

From a patient’s perspective, CIPN can be profoundly destabilising. Walking becomes uncertain. Fine motor tasks become frustrating. Sleep is disrupted. Exercise feels risky. Confidence in the body erodes.

And yet, conventional medicine has very little to offer beyond dose reduction, symptom monitoring, or medications that blunt sensation without addressing underlying nerve health.

This is where a more integrative, physiology-focused approach becomes essential.

Supporting nerve recovery is not about forcing regeneration. It’s about creating conditions where repair becomes possible.

That means:

• improving mitochondrial energy production

• reducing neuroinflammation

• supporting myelin integrity

• calming pain signalling

• and restoring metabolic resilience within the nerve itself

This is not fast work. But it is meaningful work.

Several compounds have consistently shown value in this space when used intelligently and consistently.

Benfotiamine, a fat-soluble form of vitamin B1, supports glucose metabolism within nerves and reduces the accumulation of advanced glycation end-products that impair nerve function. It has been particularly helpful in neuropathic pain states where metabolic stress is a driver.

Palmitoylethanolamide (PEA) plays a critical role in modulating neuroinflammation and mast-cell driven pain signalling. Rather than masking symptoms, it helps quiet the inflammatory noise that keeps nerves hypersensitised.

Creatine supports mitochondrial ATP production — something damaged nerves desperately need. Nerve repair is energy-dependent, and without sufficient cellular energy, regeneration stalls.

L-Carnitine assists in fatty-acid transport into mitochondria and has shown benefit in chemotherapy-related neuropathy, particularly where fatigue and nerve pain coexist.

CBG (Cannabigerol) offers non-psychoactive neuromodulation, supporting pain signalling pathways and inflammation without sedation or cognitive blunting.

None of these compounds work overnight. And none work in isolation from the broader context of recovery. But together, when used strategically, they support the biology nerves require to heal.

CIPN is not something patients should be expected to simply endure.

If you’re dealing with ongoing nerve pain, numbness, or sensory changes after chemotherapy, it’s not because you’re weak or impatient. It’s because nerve tissue heals slowly — and only when the environment supports it.

This is exactly why I’ve created a dedicated CIPN Support Stack, designed to address the core physiological drivers of chemotherapy-related nerve damage rather than just suppress symptoms.

If this article resonates, and you’re looking for a structured, evidence-informed way to support nerve recovery, you can explore the CIPN Supplement Stack in my online store HERE. It’s designed to be used consistently, intelligently, and as part of a broader recovery strategy — not as a quick fix.

Healing nerves is slow work.
But slow does not mean hopeless.

.

.

References:

Benfotiamine (Vitamin B1 derivative)

Mechanism: glucose metabolism, AGE reduction, nerve protection

1. Hammes HP et al. (2003).
   Benfotiamine blocks three major pathways of hyperglycemic damage and prevents experimental diabetic retinopathy. Nature Medicine, 9(3), 294–299.
   → Landmark paper showing benfotiamine reduces AGE formation and metabolic stress pathways.

2. Stracke H et al. (1996).
   Benfotiamine in diabetic polyneuropathy (BENDIP study). Experimental and Clinical Endocrinology & Diabetes, 104(4), 311–316.
   → Human trial showing symptom improvement in neuropathy.

3. Winkler G et al. (1999).
   Benfotiamine in treatment of diabetic polyneuropathy: randomized, double-blind study. Diabetes Care, 22(8), 1296–1301.
   → Clinical evidence of benefit in neuropathic pain states.

4. Balakumar P et al. (2010).
   The multifaceted therapeutic potential of benfotiamine. Pharmacological Research, 61(6), 482–488.
   → Review covering mitochondrial support and AGE suppression.

Note: Direct CIPN trials are limited, but neuropathic mechanism overlap (oxidative stress + glucose dysregulation) provides rationale.

Palmitoylethanolamide (PEA)

Mechanism: mast-cell modulation, neuroinflammation reduction

1. Skaper SD et al. (2014).
   Palmitoylethanolamide: a naturally occurring disease-modifying agent in neuropathic pain. CNS & Neurological Disorders - Drug Targets, 13(1), 88–95.
   → Comprehensive mechanistic review on neuroinflammation modulation.

2. Gabrielsson L et al. (2016).
   Palmitoylethanolamide for the treatment of pain: a meta-analysis. Pain Physician, 19(7), 495–506.
   → Clinical review showing neuropathic pain reduction.

3. Costa B et al. (2008).
   The endogenous fatty acid amide palmitoylethanolamide protects from paclitaxel-induced neuropathic pain in mice. Pain, 139(3), 541–550.
   → Direct relevance: PEA reduced chemotherapy-induced neuropathic pain in animal model.

4. D’Amico R et al. (2020).
   PEA in chronic pain and inflammation: update. International Journal of Molecular Sciences, 21(7), 2511.
   → Updated overview of mechanisms.

Creatine

Mechanism: ATP buffering, mitochondrial support

1. Wallimann T et al. (2011).
   The creatine kinase system and pleiotropic effects of creatine. Amino Acids, 40(5), 1271–1296.
   → Foundational review on ATP buffering and mitochondrial energetics.

2. Adhihetty PJ & Beal MF. (2008).
   Creatine and its potential therapeutic value for targeting cellular energy impairment. Pharmacology & Therapeutics, 118(3), 303–315.
   → Mitochondrial support relevance.

3. Bender A et al. (2008).
   Creatine improves health and survival of mice with Huntington disease. Neurobiology of Disease, 29(3), 350–362.
   → Demonstrates neuroprotective, energy-dependent repair relevance.

Note: Direct CIPN human trials limited, but strong mitochondrial plausibility and neuroenergetic support rationale.

L-Carnitine / Acetyl-L-Carnitine

Mechanism: fatty acid transport, mitochondrial restoration

1. Hershman DL et al. (2013).
   Randomized double-blind placebo-controlled trial of acetyl-L-carnitine for prevention of taxane-induced neuropathy. Journal of Clinical Oncology, 31(20), 2627–2633.
   → Important: This trial showed no prevention benefit and possible worsening in prevention context — important for balanced discussion.

2. Maestri A et al. (2005).
   Acetyl-L-carnitine in painful peripheral neuropathy. Journal of the Peripheral Nervous System, 10(3), 276–279.
   → Suggests benefit in neuropathic pain.

3. Flatters SJ & Bennett GJ. (2006).
   Studies on prevention of paclitaxel-induced neuropathy in rats. Pain, 122(3), 245–257.
   → Preclinical neuroprotection data.

4. Di Cesare Mannelli L et al. (2007).
   Neuroprotective effects of acetyl-L-carnitine on paclitaxel-induced neuropathy. European Journal of Pharmacology, 568(1–3), 61–67.
   → Animal data supporting repair mechanisms.

Important nuance:

• Evidence for treatment of existing neuropathy is more favourable than for prevention.

CBG (Cannabigerol)

Mechanism: non-psychoactive cannabinoid, anti-inflammatory, neuromodulatory

1. Borrelli F et al. (2013).
   Beneficial effect of the non-psychotropic plant cannabinoid cannabigerol on experimental inflammatory bowel disease. Biochemical Pharmacology, 85(9), 1306–1316.
   → Demonstrates anti-inflammatory mechanism.

2. Nachnani R et al. (2021).
   The pharmacological case for cannabigerol. Frontiers in Pharmacology, 12, 683475.
   → Mechanistic overview.

3. Rock EM et al. (2011).
   Cannabinoids in neuropathic pain. British Journal of Pharmacology, 163(7), 1416–1427.
   → Broader cannabinoid analgesic mechanisms (not CBG-specific but mechanistically relevant).